Scholars@Duke
Susan Halabi

Susan Halabi CV

James B. Duke Distinguished Professor of Biostatistics & Bioinformatics
Biostatistics & Bioinformatics, Division of Biostatistics
susan.halabi@duke.edu
Duke Box 2717, Durham, NC 27710
2424 Erwin Road 11th Floor, 11088 Hock Plaza, Durham, NC 27705
CV

Overview

Design and analysis of clinical trials, statistical analysis of biomarker and high dimensional data, development and validation of prognostic and predictive models.

Current Duke Appointments & Affiliations

James B. Duke Distinguished Professor of Biostatistics & Bioinformatics · 2023 - Present Biostatistics & Bioinformatics, Division of Biostatistics, Biostatistics & Bioinformatics
Professor of Biostatistics & Bioinformatics · 2012 - Present Biostatistics & Bioinformatics, Division of Biostatistics, Biostatistics & Bioinformatics
Chief, Division of Biostatistics · 2019 - Present Biostatistics & Bioinformatics, Basic Science Departments
Member of the Duke Cancer Institute · 1996 - Present Duke Cancer Institute, Institutes and Centers

Recent News Items

Published February 12, 2025
New Blood Test for Advanced Prostate Cancer Patients
Published May 4, 2023
Duke Awards 44 Distinguished Professorships
Published June 3, 2018
Survival Benefit for African-Americans with Advanced Prostate Cancer

View All News Items

Recent Scholarly Works

AI-based augmentation of oncology clinical trials.

Journal article Nat Rev Clin Oncol · August 7, 2026 Oncology clinical trials are often characterized by slow accrual, high failure rates and limited generalizability, reflecting both biological complexity and operational inefficiencies. Advances in artificial intelligence (AI) - enabled by large-scale elect ... Full text Link to item Cite

Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study.

Journal article JCO Precis Oncol · July 2026 PURPOSE: The Targeted Agent and Profiling Utilization Registry Study is a phase II basket trial evaluating the antitumor activity of commercially available targeted agents in patients with advanced cancer and genomic alterations. Results of a cohort of pat ... Full text Link to item Cite
View All Scholarly Works

Recent Grants

Prostate Cancer Research Program Clinical Consortium Award

ResearchCo Investigator · Awarded by Department of Defense · 2026 - 2030

The COVID-19 and Cancer Consortium (CCC19) Registry

ResearchPrincipal Investigator · Awarded by Rhode Island Hospital · 2024 - 2029

Assessing Prognoses and Validating Surrogate Endpoints for Clinical Outcomes in Metastatic Hormone Sensitive Prostate Cancer

ResearchPrincipal Investigator · Awarded by Department of Defense · 2025 - 2028

View All Grants

Education

University of Texas Health Sciences Center, Houston · 1994 Ph.D.

External Links

Prostate Cancer Nomograms for Predicting Overall Survival curriculum vitae